AGUETTANT
ESSENTIAL
MEDICINES

Aguettant Limited

Transparency Disclosure 2020

Methodological Notes

Aguettant Limited is not an ABPI member, however, the company has given formal agreement to abide by the ABPI Code of Practice and accept the jurisdiction of the PMCPA.

Procedure

The transfers of value which were considered for the 2019 disclosure are covered by Clause 24 of the

ABPI Code of Practice 2019:

- joint working in accordance with Clause 20 of the ABPI Code of Practice 2019

- donations, grants and benefits in kind provided to institutions, organisations and associations in accordance with Clauses 19.1 and 19.2 of the ABPI Code of Practice 2019

- contracts between companies and institutions, organisations and associations in accordance with Clause 21 of the ABPI Code of Practice 2019

- sponsorship of attendance by health professionals and other relevant decision makers at meetings in accordance with Clause 22.5 of the ABPI Code of Practice 2019

- fees and expenses paid to health professionals and other relevant decision makers, or to their employers on their behalf, in accordance with Clauses 23.2, 23.3 and 23.4 of the ABPI Code of Practice 2019

- contributions towards the costs of meetings paid to healthcare organisations or to third parties managing events on their behalf, which may include sponsorship of health professionals by way of registration fees and accommodation and travel

Aguettant Limited contemporaneously record any transfers of value made by Aguettant Ltd, their parent Company and other affiliates to UK Healthcare Professionals (HCPs), Other Relevant Decision Markers (ORDMs) or Healthcare Organisation (HCO).

All transfer of value spends have been collated manually using a centralised spreadsheet. The records have been reconciled and confirmed internally a month before the disclosure to ensure the entirety of the transfers of value have been captured.

Data Privacy

Data Privacy law requires Aguettant Limited to obtain permission from individual HCPs or HCOs prior to disclosing personal data such as individual transfers of value. HCPs or HCOs have agreed on the transparency disclosure by signing their contracts with Aguettant Limited.

Payment dates and reporting period

Only payments made in 2020 are disclosed.

Currency

Aguettant Ltd
No 1 Farleigh House, Old Weston Road, Flax Bourton, Bristol, BS48 1UR, United Kingdom
Tel. 01275 463691 - Fax: 08443 650050 - Email: info@aguettant.co.uk
Registered in England 4966231 VAT 832649416 WL 20825/1

Where payments had been made in local currency other than GBP, the amount in GBP has been calculated using the published HMRC monthly exchange rate at the time the payment was made.

VAT

Transfer of value disclosure is presented exclusive of VAT except where VAT could not be reclaimed.

2020 Transparency Disclosure

In 2019, Aguettant's transfer of value to UK HCPs and HCOs related to:

- Consultancy Fees paid to HCPs (Speaker and Advisor):

02 speakers were paid in 2020 for a medical presentation in injectable drug safety.

- Contributions to cost of events:

Aguettant Limited participated in no exhibitions, meetings or events, and paid fees to HCOs or third-party event organisers for exhibition packages that included attendance fees, stand and/or room rental.

- Donations, Grants and Benefits in Kind to HCOs:

None

All transfers of value made by Aguettant Limited, their parent Company and other affiliates from 01 January until 31 December 2020 have been disclosed on the central platform managed by the ABPI.

Date of Preparation: March 2020

Aguettant Ltd
No 1 Farleigh House, Old Weston Road, Flax Bourton, Bristol, BS48 1UR, United Kingdom
Tel. 01275 463691 - Fax: 08443 650050 - Email: info@aguettant.co.uk
Registered in England 4966231 VAT 832649416 WL 20825/1